热休克蛋白90在肺癌诊治中的研究进展

The research advancement of heat shock protein 90 on lung cancer diagnosis and therapy

肺癌的发病率和病死率在中国居各类肿瘤之首，热休克蛋白90（heatshockprotein90，Hspg0）作为重要的分子伴侣参与调控和维持细胞内多种肿瘤相关蛋白的构象和功能，通过抑制Hsp90能抑制实体瘤如肺癌、乳腺癌、前列腺癌等的侵袭和转移。因此，Hspg0抑制剂作为治疗晚期非小细胞肺癌的抗肿瘤药物目前已进入美国临床试验，在单药治疗、联合治疗以及对EGFR—TKI／Crizotinib耐药的非小细胞肺癌患者Ⅰ、Ⅱ期临床试验中取得了良好的效果。而血清中的Hsp90a亦可作为肺癌诊断、治疗和判断预后的良好监测指标。本文将对Hsp90在肺癌的诊治方面的现状和研究进展进行综述。

Lung cancer is the most common pathogenesis of cancer morbidity and mortality in China. As a key molecular chaperone, heat shock protein 90 （Hsp90） is crucial for regulation and maintaining the conformation and function of oncogenic proteins. Furthermore, inhibition of Hsp90 has an antitumor effect in some solid tumors like lung cancer, breast cancer and prostate cancer. So Hsp90 inhibitors which have shown promising anti-tumor activity in non-small cell lung carcinoma （NSCLC） are currently in clinical trial by single agents or in combination with other therapies. The results show that good consequence in NSCLC patients who are resistant to EGFR-TKI/crizotinib in phase Ⅰ and Ⅱ clinical trial. Besides plasma Hsp90a protein level are useful as a good biomarker for diagnostic in lung cancer and predict the responses of chemotherapy for NSCLC patients. Here, we review the recent clinical and basic research about Hspg0 in diagnosis and treatment on lung cancer.